4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by Geri Gentry on Aug 24th, 2026

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $29.6250.

A number of equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

View Our Latest Analysis on FDMT

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $15.83 on Monday. The company has a market capitalization of $874.45 million, a PE ratio of -6.02 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a fifty day moving average of $11.61 and a 200-day moving average of $10.12. 4D Molecular Therapeutics has a one year low of $5.97 and a one year high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. As a group, equities analysts anticipate that 4D Molecular Therapeutics will post -4.09 EPS for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the transaction, the insider owned 871,737 shares in the company, valued at approximately $8,760,956.85. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 200,496 shares of company stock valued at $2,240,244. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter worth about $1,936,000. Dimensional Fund Advisors LP boosted its position in 4D Molecular Therapeutics by 77.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after acquiring an additional 227,982 shares during the period. Exome Asset Management LLC purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $1,216,000. Perigon Wealth Management LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $1,944,000. Finally, Evergreen Quality Fund GP Ltd. purchased a new position in 4D Molecular Therapeutics during the 4th quarter valued at about $7,136,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.